1.
$Intellia Therapeutics(NTLA)$ had a strong Q2, with key trials moving faster than expected and cash to fund operations into 2027.
CEO John Leonard said, “We are exceeding many of our internal expectations.”
The company is making steady progress toward its first commercial launch, with major data updates and a BLA filing expected in 2025–2026. With growing momentum, the outlook is full of potential.
Image
2.
$Constellation Energy Corp(CEG)$ delivered a standout Q2, with adjusted EPS of $1.91 and a reaffirmed full-year outlook of $8.90–$9.60, driving shares up 8%.
Backed by strong commercial performance and key milestones like the Meta deal and Crane restart, growth momentum is accelerating. As CEO Joe Dominguez stated, “We’re doing our part to ensure reliability and affordability.”
With bipartisan support for nuclear energy and the Calpine acquisition on track, Constellation is positioned to lead the clean energy transition while delivering double-digit EPS growth through 2030.
The outlook remains strong.
Image
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here：
Comments